bioRxiv · 10.1101/2021.02.11.430866
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Abstract
Coronaviruses have caused several epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Some prophylactic vaccines and therapeutic antibodies have already showed striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody CV38-142 in complex with the receptor binding domains from SARS-CoV-2 and SARS-CoV. Our structural findings provide mechanistic insights into how this antibody can accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, in particular COVA1-16, to enhance neutralization of SARS-CoV-2 and SARS-CoV. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and to protect against zoonotic coronaviruses.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, H., Yuan, M., Huang, D., Bangaru, S., Lee, C.-C. D., Peng, L., Zhu, X., Nemazee, D., van Gils, M. J., Sanders, R. W., Kornau, H.-C., Reincke, S. M., Pruss, H., Kreye, J., Wu, N. C., Ward, A. B., Wilson, I. A.. 2021-02-12. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. https://doi.org/10.1101/2021.02.11.430866
Cite the original work for its findings. Save a collection to share your selection of sources.